Mineralys Therapeutics (NASDAQ:MLYS) Posts Earnings Results, Misses Estimates By $2.30 EPS

Mineralys Therapeutics (NASDAQ:MLYS) announced its earnings results on Wednesday. The company reported ($2.85) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.55) by ($2.30), FiscalAI reports.

Mineralys Therapeutics Stock Down 3.5%

Shares of NASDAQ MLYS opened at $26.09 on Friday. The business has a fifty day simple moving average of $26.44 and a two-hundred day simple moving average of $27.55. The firm has a market cap of $2.31 billion, a PE ratio of -6.15 and a beta of 0.68. Mineralys Therapeutics has a twelve month low of $13.40 and a twelve month high of $47.65.

Mineralys Therapeutics News Roundup

Here are the key news stories impacting Mineralys Therapeutics this week:

• Positive Sentiment: FDA decision and launch preparations remain on track: Mineralys reiterated a December 22, 2026 PDUFA date for lorundrostat, its investigational hypertension treatment, and said commercial launch preparations are progressing. Launch readiness and cash runway
• Positive Sentiment: Cash runway provides financial flexibility: Management said its cash position should fund operations into 2028, reducing near-term financing risk as the company advances toward a potential launch. The company also highlighted actions intended to improve lorundrostat’s long-term economics. Second-quarter earnings call highlights
• Positive Sentiment: Near-term EPS estimates improved: HC Wainwright raised its Q3 2026 EPS forecast to a loss of $0.56 from $0.61 and its Q4 forecast to a loss of $0.60 from $0.70, while retaining its Buy rating.
• Neutral Sentiment: New chief medical officer appointed: Mineralys granted Dr. Terry Ferguson inducement awards covering 135,000 stock options and 102,400 restricted stock units. The appointment strengthens late-stage development leadership, although the equity awards create potential dilution. Inducement award announcement
• Negative Sentiment: Large quarterly earnings miss: Mineralys reported a second-quarter loss of $2.85 per share, far worse than the $0.55 consensus loss, increasing concerns about spending and execution even though the company remains pre-commercial. Second-quarter earnings call transcript
• Negative Sentiment: Long-term earnings outlook was reduced: HC Wainwright cut its FY2026 EPS estimate to a $4.47 loss from $2.33, FY2027 to a $3.78 loss from $2.84, FY2028 to a $2.27 loss from $1.52, and FY2029 profit to $0.42 from $0.92. It also lowered FY2030 profit expectations to $3.41 from $3.73.
• Negative Sentiment: Insider selling adds a modest cautionary signal: David Malcom Rodman sold 2,170 shares worth approximately $58,785 under a pre-arranged Rule 10b5-1 plan, reducing his holdings by 4.05%. Insider sale disclosure

Insider Buying and Selling at Mineralys Therapeutics

In related news, insider David Malcom Rodman sold 2,170 shares of the business’s stock in a transaction that occurred on Monday, August 10th. The shares were sold at an average price of $27.09, for a total value of $58,785.30. Following the completion of the transaction, the insider owned 51,384 shares of the company’s stock, valued at $1,391,992.56. The trade was a 4.05% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available at the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director Daphne Karydas sold 3,000 shares of the business’s stock in a transaction that occurred on Wednesday, June 17th. The stock was sold at an average price of $25.00, for a total transaction of $75,000.00. Following the completion of the transaction, the director directly owned 6,200 shares of the company’s stock, valued at $155,000. This trade represents a 32.61% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. In the last 90 days, insiders have sold 217,313 shares of company stock worth $5,624,488. 18.94% of the stock is owned by company insiders.

Institutional Inflows and Outflows

Several large investors have recently made changes to their positions in the stock. RA Capital Management L.P. boosted its position in Mineralys Therapeutics by 19.1% during the third quarter. RA Capital Management L.P. now owns 7,323,750 shares of the company’s stock valued at $277,717,000 after purchasing an additional 1,176,470 shares in the last quarter. State Street Corp raised its holdings in Mineralys Therapeutics by 144.4% in the fourth quarter. State Street Corp now owns 3,184,999 shares of the company’s stock worth $115,584,000 after purchasing an additional 1,881,976 shares in the last quarter. Caligan Partners LP raised its holdings in Mineralys Therapeutics by 37.4% in the third quarter. Caligan Partners LP now owns 2,772,654 shares of the company’s stock worth $105,139,000 after purchasing an additional 755,302 shares in the last quarter. Franklin Resources Inc. lifted its position in shares of Mineralys Therapeutics by 0.3% during the third quarter. Franklin Resources Inc. now owns 1,809,768 shares of the company’s stock valued at $68,626,000 after buying an additional 6,171 shares during the last quarter. Finally, Orbimed Advisors LLC lifted its position in shares of Mineralys Therapeutics by 93.3% during the third quarter. Orbimed Advisors LLC now owns 1,469,494 shares of the company’s stock valued at $55,723,000 after buying an additional 709,143 shares during the last quarter. 84.46% of the stock is owned by institutional investors.

Analysts Set New Price Targets

A number of equities analysts recently commented on MLYS shares. TD Cowen initiated coverage on Mineralys Therapeutics in a report on Monday, April 27th. They issued a “buy” rating on the stock. Weiss Ratings reiterated a “sell (d-)” rating on shares of Mineralys Therapeutics in a research note on Friday, July 17th. Wall Street Zen cut shares of Mineralys Therapeutics from a “hold” rating to a “sell” rating in a research report on Saturday, May 9th. HC Wainwright restated a “buy” rating on shares of Mineralys Therapeutics in a report on Monday, June 1st. Finally, Jefferies Financial Group restated a “hold” rating on shares of Mineralys Therapeutics in a research report on Monday, June 1st. Six analysts have rated the stock with a Buy rating, one has given a Hold rating and one has issued a Sell rating to the company. According to data from MarketBeat, Mineralys Therapeutics currently has a consensus rating of “Moderate Buy” and a consensus target price of $49.33.

About Mineralys Therapeutics

Mineralys Therapeutics, Inc, a clinical-stage biopharmaceutical company that develops therapies for the treatment of hypertension and chronic kidney diseases. It clinical-stage product candidate is lorundrostat, a proprietary, orally administered, highly selective aldosterone synthase inhibitor for the treatment of cardiorenal conditions affected by abnormally elevated aldosterone. The company was formerly known as Catalys SC1, Inc and changed its name to Mineralys Therapeutics, Inc in May 2020. The company was incorporated in 2019 and is headquartered in Radnor, Pennsylvania.